Nilotinib in Parkinson's Disease (NILO-PD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03205488 |
|
Recruitment Status :
Completed
First Posted : July 2, 2017
Results First Posted : July 22, 2020
Last Update Posted : July 22, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson Disease | Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) Drug: Placebo | Phase 2 |
The purpose of this study is to determine if nilotinib is safe, if it can be tolerated by patients with Parkinson's disease (PD) and to learn if nilotinib has the possibility of effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug Administration (FDA) to treat certain types of cancer (leukemia) but is considered investigational in this study because it has not been approved for treating PD. Twenty-five sites will enroll participants into 2 cohorts,approximately 75 in Cohort 1 and 60 in Cohort 2. Participants with moderate to advanced PD symptoms will be enrolled in Cohort 1, randomly assigned to take nilotinib (150 mg or 300mg) or placebo, and will complete 13 in-person study visits over 8.5 months.
The results from Cohort 1 will determine if either dose of nilotinib (150mg or 300 mg) is safe and tolerable enough to move forward and evaluate in Cohort 2. If either dose is found to be safe and tolerable, participants with early PD will be enrolled into Cohort 2.
Participants in Cohort 2 will be randomly assigned to either nilotinib (dose to be determined from Cohort 1 results) or placebo and will complete 17 in-person visits over 14.5 months. For both cohorts, the study visits will include clinical assessment of motor, neuropsychiatric and cognitive testing as well as collection of blood and cerebral spinal fluid, collected by lumbar puncture.
This study will also evaluate if nilotinib can help improve motor symptoms associated with PD. All participants in Cohort 1 and participants in Cohort 2 who have started PD medications will have an assessment of the motor exam (Part III) in a practically defined OFF state (12 hours post dose) and ON state (at least one-hour post dose).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 76 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease |
| Actual Study Start Date : | October 16, 2017 |
| Actual Primary Completion Date : | August 26, 2019 |
| Actual Study Completion Date : | September 28, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Cohort 1
Moderate to Advanced PD Population Randomized 1:1:1
|
Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
2 capsules taken once daily Drug: Placebo 2 capsules taken once daily |
|
Active Comparator: Cohort 2
Early/de novo Randomized 2:1
|
Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
2 capsules taken once daily Drug: Placebo 2 capsules taken once daily |
- Tolerability of Nilotinib Over Placebo [ Time Frame: 6 months ]The count of study participants who completed the 6-month study treatment period while active on their original assigned dose
- Safety of Nilotinib [ Time Frame: We assessed adverse events that were collected from the first dose of study drug until 60 days after the participant's last dose. ]The count of study participants who experienced any treatment-related SAE in each treatment group
- Change in MDS-UPDRS Part III [ Time Frame: The MDS-UPDRS Part III ON state was collected at baseline, day 14, day 30, month 3, month 6, 30 and 60 days post treatment. The OFF state was collected at baseline, month 3, month 6, 30 and 60 days post treatment. ]The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III is a motor examination in both practically defined medications OFF state (12 hrs post dose) and ON state (based on the participant/site investigator defined best ON and/or approximately 1 hour post dose). Measure Description: The part III subscale score ranges from 0-165. The Larger the value stands for more disability from PD.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 79 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria; Cohort 1 and 2:
- Idiopathic PD based on the UK Brain Bank diagnostic criteria.
- Any race and either gender, age 40-79
- Able to read and understand English with the capacity to provide voluntary informed consent by signing the informed consent form (ICF)
- Willing to comply with all study procedures including multiple lumbar punctures (LP)
- Must be on a stable regimen of central nervous system acting medications (if applicable) for at least 30 days prior to the baseline visit (e.g., benzodiazepines, antidepressants, hypnotics)
Inclusion criteria specific for Cohort 1:
6a. Diagnosis of PD duration > 5 year 7a. Hoehn & Yahr scale (H&Y) stage > 2 and < 4 in the ON state 8a. Must be on a stable regimen of PD medications, that includes levodopa, for at least 30 days prior to the screening visit
a. Treatment with monoamine oxidase B (MAO-B) inhibitors will be allowed provided the dose has been stable for 60 days prior to baseline
Inclusion criteria specific for Cohort 2:
6b. Diagnosis of PD duration < 3 years 7b. H&Y stage ≤ 2 8b. Participants who are currently NOT receiving symptomatic therapy (ST) (levodopa,dopamine agonists and monoamine oxidase B (MAO-B) inhibitors) and NOT projected to require ST for at least 3 months from enrollment.
a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose has been stable for 30 days prior to screening and will remain stable for the duration of the study
Exclusion Criteria; Cohorts 1 and 2:
- Diagnosis of atypical parkinsonism
- History of bipolar disorder or major depression, or presence of active depression defined as a Beck Depression Inventory II (BDI-II) score >17
- History of a suicide attempt within the last 5 years or active suicidal ideations
- History of schizophrenia or schizophrenia spectrum disorders
- History of uncontrolled hypokalemia or hypomagnesaemia, or laboratory evidence of such on screening
- History of cardiac arrhythmia, long QT syndrome, or a corrected QT interval (QTcF) ≥450ms at screening visit 1
-
Treated within 30 days prior to randomization, or planned use during the trial with any of the following classes of Concomitant drugs:
- Class IA or III antiarrhythmic drugs
- QT prolonging drugs
- Strong CYP3A4 inhibitors or inducers
- Anticoagulants
- Proton pump inhibitors
-
A clinical history, or the active presence of a cardiovascular condition including:
- Myocardial infarction, known cardiac ischemia, or angina
- Cerebrovascular event (e.g. embolic stroke)
- Congestive heart failure, symptomatic first degree atrioventricular (AV) block or PR interval > 220msec and all second and third degree AV block, second- or third-degree atrioventricular block, sick sinus syndrome, or other serious cardiac rhythm disturbances
- History of Torsade de Pointes
- Other cardiovascular history that, in the opinion of the Site Investigator, will preclude study participation
- History of hepatic disease, including abnormal liver function defined as Total Bilirubin > 1.5 times upper limit, Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) > 2 times the upper limit of the normal, or coagulopathy with INR > 1.4
- History of epilepsy or a seizure within the last 6 months
- Active malignancy, or history of a neoplasm in the prior 5 years (excluding basal/squamous cell carcinoma)
- Prior history of pancreatitis or total gastrectomy or evidence of abnormal pancreatic function defined as elevated amylase and/or lipase > 2 times upper limit of normal
- Diagnosis of human immunodeficiency virus (HIV), clinically significant chronic hepatitis such as hepatitis B (HBV) or hepatitis C (HCV), or clinical history or signs of an active infection
- History of drug or alcohol abuse ≤ 5 years
- Active medical or psychiatric condition that in the opinion of the Site Investigator should preclude study participation
- Previous surgical management for PD
- Participants participating in any drug or device clinical investigation concurrently or within 30 days prior to screening for this study
- Severe lactose and galactose intolerance
- Participants with evidence of other significant laboratory abnormalities which in the opinion of the site investigator or clinical monitor should preclude study participation
- Known hypersensitivity or contraindication to study drugs (nilotinib or matching placebo) or their components.
- Female participants of child-bearing potential. Female participants must be post-menopausal, post-hysterectomy, or have a documented infertility based on a known medical or surgical condition
- Participants with a history of bone marrow suppression or evidence of persistent myelosuppression defined as absolute neutrophil count <1.8 X 109/L, significant anemia, or thrombocytopenia defined as platelet count < 100 X 109/L
Exclusion criteria specific for Cohort 1:
22a. Diagnosis of dementia based on the clinician's assessment, or a Montreal Cognitive Assessment (MoCA) score < 21 at baseline
Exclusion criteria specific for Cohort 2:
22b.MoCA score < 26 at baseline 23b. Treated within 60 days prior to randomization or expected to require treatment within 3 months from randomization with any ST (including levodopa and dopamine agonists )
a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose has been stable for 30 days prior to screening and will remain stable for the duration of the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03205488
Show 24 study locations
| Principal Investigator: | Tanya Simuni, MD | Northwestern University |
Documents provided by Tanya Simuni, Northwestern University:
| Responsible Party: | Tanya Simuni, Director, Parkinson's disease and Movement Disorders Center Northwestern University Feinberg School of Medicine, Northwestern University |
| ClinicalTrials.gov Identifier: | NCT03205488 |
| Other Study ID Numbers: |
NILO-PD |
| First Posted: | July 2, 2017 Key Record Dates |
| Results First Posted: | July 22, 2020 |
| Last Update Posted: | July 22, 2020 |
| Last Verified: | July 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Northwestern Nilotinib USA NILO-PD Parkinson Disease |
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |